<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1139">
  <stage>Registered</stage>
  <submitdate>25/02/2006</submitdate>
  <approvaldate>1/03/2006</approvaldate>
  <actrnumber>ACTRN12606000086561</actrnumber>
  <trial_identification>
    <studytitle>The effect of Dexmedetomidine on MAAS in severely agitated, mechanicaaly ventilated, critically ill patients</studytitle>
    <scientifictitle>The effect of Dexmedetomidine on MAAS in severely agitated, mechanicaaly ventilated, critically ill patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Agitation in mechanically ventilated ICU patients.</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients who meet the inclusion creteria were given a continuous intravenous infusion of Dexmedetomidine (0.4 - 1.0mic/kg/hr) up to 7 days.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Motor Activity Assessment Score (MASS)</outcome>
      <timepoint>At 6 and 12 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Length of mechanical ventilation in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Ventilation time pre Dexmedetomidine in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Ventilation time post Dexmedetomidine in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Number of patients extubated whilst on  Dexmedetomidine in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Number of tracheostomy in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. Number of self extubation in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>7. Number of reintubations in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8. Use of other sedatives in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>9. Use of vasopressor and vasodilator infusions in ICU</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Patient requiring invasive ventilation for longer than 24 hours. 2.Receiving narcotics and /or sedatives for longer than 24 hours. 3.Development of clinical agitation and/or delirium upon weaning narcotics and/or sedatives on commencement of weaning from mechanical ventilation 4.Informed consent signed by person responsible within 24 hours of enrolment. 5. Have failed conventional sedative therapy as assessed by the treating intensivist.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Allergy to Dexmedetomidine.2.Patients who are or likely to be pregnant or lactating.3.Patients receiving other long term alpha 2 agonists.4. Involvement in a sedation study within the last 30 days.5. Known opiate or benzodiazepines dependence, treatment for chronic pain or recent detoxification therapy within the last 6 months. 6. Patients on anti-psychotic drugs  7. Known dementia, Parkinsonism or epilepsy.8. Patients with recent cerebro-vascular surgery or traumatic brain injury.9. Any evidence of critical illness polyneuropathy.10. Recent surgery involving free flap.11. Haemodynamically unstable patients with Systolic blood pressure &lt; 90 mmHg and or Heart rate &lt; 55 / min.12. Patients on CVVHD.13. Patients with hepatic encephalopathy within 14 days.14. Patients with a recent drug overdose or CO poisoning.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Prince of Wales Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Intensive care research fund</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Yahya Shehabi</name>
      <address>Intensive Care Unit
Prince of Wales Hospital
Level 1
Dickinson Building
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93824721</phone>
      <fax />
      <email>yshehabi@ozemail.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Naomi Hammond</name>
      <address>Intensive Care Unit
Prince of Wales Hospital
Level 1
Dickinson Building
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93824720</phone>
      <fax />
      <email>naomi.hammond@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>